HN2012001351A - Derivados de 3- hidroxi-5-arilisotiazol novedosos - Google Patents

Derivados de 3- hidroxi-5-arilisotiazol novedosos

Info

Publication number
HN2012001351A
HN2012001351A HN2012001351A HN2012001351A HN2012001351A HN 2012001351 A HN2012001351 A HN 2012001351A HN 2012001351 A HN2012001351 A HN 2012001351A HN 2012001351 A HN2012001351 A HN 2012001351A HN 2012001351 A HN2012001351 A HN 2012001351A
Authority
HN
Honduras
Prior art keywords
compound
salt
ring
novedosos
arilisotiazol
Prior art date
Application number
HN2012001351A
Other languages
English (en)
Inventor
Akihiro Okano
Naoto Kosuga
Munetaka Ohkouchi
Daido Hotta
Muneyoshi Makabe
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of HN2012001351A publication Critical patent/HN2012001351A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PROPORCIONAR UN AGENTE QUE ACTIVA GPR40 QUE TIENE, COMO UN INGREDIENTE ACTIVO, UN COMPUESTO NOVEDOSO QUE TIENE UNA ACCION AGONISTA GPR40, UNA SAL DEL COMPUESTO, UN SOLVATE DE LA SAL O EL COMPUESTO, O SIMILARES, PARTICULARMENTE, UN SECRETAGOGO DE INSULINA Y Y UN AGENTE TERAPEUTICO Y/O PROFILACTICO CONTRA DIABETES, OBESIDAD, U OTRAS ENFERMEDADES. MEDIOS PARA SOLUCIONAR EL PRBLEMA UN COMPUESTO DE LA FORMULA ( I ): DONDE N ES O HASTA 2; P ES O HASTA 4; J ES O HASTA 3; K ES O HASTA 2; UN ANILLO A ES UN GRUPO ARILO QUE ESTA OPCIONALMENTE SUSTITUIDO CON L O UN GRUPO HETEROCICLICO QUE ESTA OPCIONALMENTE SUSTITUIDO CON L; UN ANILLO B ES UN ANILLO 20 DE BENCENO, UN ANILLO DE PIRIDINA, O UN ANILLO DE PIRIDINA; X ES O, S,- NR7 -; Y R1 HASTA R7 SON GRUPOS ESPECIFICOS, UNA SAL DEL COMPUESTO, O UN SOLVATO DE LA SAL O EL COMPUESTO.
HN2012001351A 2009-12-25 2012-06-25 Derivados de 3- hidroxi-5-arilisotiazol novedosos HN2012001351A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009295855 2009-12-25
JP2010043420 2010-02-26

Publications (1)

Publication Number Publication Date
HN2012001351A true HN2012001351A (es) 2015-03-23

Family

ID=44195895

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2012001351A HN2012001351A (es) 2009-12-25 2012-06-25 Derivados de 3- hidroxi-5-arilisotiazol novedosos

Country Status (25)

Country Link
US (1) US8476287B2 (es)
EP (1) EP2518060A4 (es)
JP (2) JP5002077B2 (es)
KR (1) KR20130004262A (es)
CN (2) CN104710381A (es)
AU (1) AU2010336225A1 (es)
BR (1) BR112012015612A2 (es)
CA (1) CA2785674A1 (es)
CL (1) CL2012001722A1 (es)
CO (1) CO6650337A2 (es)
CR (1) CR20120345A (es)
EA (1) EA201290574A1 (es)
EC (1) ECSP12012056A (es)
GT (1) GT201200217A (es)
HN (1) HN2012001351A (es)
IL (1) IL220616A0 (es)
MA (1) MA33952B1 (es)
MX (1) MX2012007474A (es)
NI (1) NI201200113A (es)
NZ (1) NZ601408A (es)
PE (1) PE20121639A1 (es)
RU (1) RU2567755C2 (es)
SG (1) SG181961A1 (es)
WO (1) WO2011078371A1 (es)
ZA (1) ZA201203416B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779398A1 (en) 2009-10-30 2011-05-05 Mochida Phamaceutical Co., Ltd. Novel 3-hydroxy-5-arylisoxazole derivative
NZ601408A (en) 2009-12-25 2013-12-20 Mochida Pharm Co Ltd Novel 3-hydroxy-5-arylisothiazole derivative
US8581584B2 (en) * 2010-05-26 2013-11-12 Florida State University Research Foundation Membrane proteins, mechanisms of action and uses thereof
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
JP5728099B2 (ja) 2011-02-25 2015-06-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体
AU2012248629A1 (en) * 2011-04-27 2013-11-28 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxyisothiazole 1-oxide derivative
AU2012248627A1 (en) * 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013154163A1 (ja) * 2012-04-11 2013-10-17 持田製薬株式会社 新規５－アリール－１，２－チアジナン誘導体
KR102089239B1 (ko) 2012-04-24 2020-03-16 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3527563B1 (en) 2013-03-12 2021-09-01 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2705342T3 (es) 2013-10-17 2019-03-22 Vertex Pharma Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
US10011609B2 (en) 2013-11-14 2018-07-03 Cadila Healthcare Limited Heterocyclic compounds
CN107708690B (zh) * 2015-02-27 2021-09-14 常山凯捷健生物药物研发（河北）有限公司 作为激酶抑制剂的嘧啶衍生物和它们的治疗应用
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated CANCER TREATMENT METHOD USING A COMBINATION OF DNA DAMAGING AGENTS AND DNA-PK INHIBITORS
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
UA126458C2 (uk) 2018-02-13 2022-10-05 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN110066254B (zh) * 2018-11-16 2021-03-19 温州大学 一种异噻唑-3-酮化合物的制备方法
EP4041722A4 (en) 2019-10-07 2023-12-13 Kallyope, Inc. GPR119 AGONISTS
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN115433143B (zh) * 2021-06-03 2023-10-13 中国科学院大连化学物理研究所 一种异噻唑啉酮类化合物的合成方法
CN115386028B (zh) * 2022-08-26 2023-06-23 长春理工大学 一种聚合度可控的聚山梨酸-d-薄荷醇酯及合成方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562283A (en) 1968-07-01 1971-02-09 Rohm & Haas 1-oxo and 1,1-dioxo-3-isothiazolones
US3801575A (en) * 1972-01-24 1974-04-02 Rohm & Haas 3-hydroxyisothiazoles
EP0885891A4 (en) 1996-02-27 2001-02-21 Sankyo Co ISOXAZOLE DERIVATIVES
AP2001002225A0 (en) 1999-01-13 2001-09-30 Warner Lambert Co 1-heterocycle substituted diarylamines.
JP2000204077A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
AU2003263814A1 (en) 2002-07-26 2004-02-16 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
CA2497901A1 (en) 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
JP4594611B2 (ja) 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
CA2551610A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
EP1912645A2 (en) 2005-08-10 2008-04-23 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
PE20080993A1 (es) 2006-06-27 2008-10-06 Takeda Pharmaceutical Compuestos ciclicos fusionados como moduladores del receptor gpr40
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
WO2008033931A1 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
CA2668713C (en) 2006-12-01 2015-09-08 Banyu Pharmaceutical Co., Ltd. Novel phenyl-isoxazol-3-ol derivative
US7572934B2 (en) 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
CA2700028A1 (en) 2007-09-21 2009-04-02 Sanofi-Aventis (carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament
AU2008311355B2 (en) 2007-10-10 2012-01-19 Amgen Inc. Substituted biphenyl GPR40 modulators
JP2011016722A (ja) 2007-10-23 2011-01-27 Astellas Pharma Inc チアゾリジンジオン化合物
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
PT2202216E (pt) 2007-10-26 2012-07-19 Japan Tobacco Inc Composto espiro em anel e sua utilização para objectivos médicos
CA2716352C (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US20110065739A1 (en) 2008-06-02 2011-03-17 Makoto Ishikawa Novel isoxazole drivative
EP2289868B1 (en) 2008-06-25 2014-08-13 Daiichi Sankyo Company, Limited Carboxylic acid compound
US20110312995A1 (en) 2009-01-23 2011-12-22 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
AR075051A1 (es) 2009-02-05 2011-03-02 Schering Corp Compuestos antidiabeticos que contienen ftalazina
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
CA2779398A1 (en) 2009-10-30 2011-05-05 Mochida Phamaceutical Co., Ltd. Novel 3-hydroxy-5-arylisoxazole derivative
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
NZ601408A (en) 2009-12-25 2013-12-20 Mochida Pharm Co Ltd Novel 3-hydroxy-5-arylisothiazole derivative
CN101781268B (zh) 2010-02-25 2012-05-30 中国人民解放军军事医学科学院毒物药物研究所 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative

Also Published As

Publication number Publication date
NI201200113A (es) 2012-08-13
ZA201203416B (en) 2013-08-28
CA2785674A1 (en) 2011-06-30
US20120157459A1 (en) 2012-06-21
WO2011078371A1 (ja) 2011-06-30
CN104710381A (zh) 2015-06-17
EA201290574A1 (ru) 2012-12-28
RU2567755C2 (ru) 2015-11-10
PE20121639A1 (es) 2012-12-02
MX2012007474A (es) 2012-08-01
BR112012015612A2 (pt) 2016-03-15
CL2012001722A1 (es) 2012-12-14
JPWO2011078371A1 (ja) 2013-05-09
SG181961A1 (en) 2012-08-30
US8476287B2 (en) 2013-07-02
EP2518060A1 (en) 2012-10-31
JP5002077B2 (ja) 2012-08-15
IL220616A0 (en) 2012-08-30
AU2010336225A1 (en) 2012-08-16
KR20130004262A (ko) 2013-01-09
CO6650337A2 (es) 2013-04-15
GT201200217A (es) 2014-02-10
RU2012131840A (ru) 2014-01-27
JP2012153726A (ja) 2012-08-16
CR20120345A (es) 2012-11-01
NZ601408A (en) 2013-12-20
EP2518060A4 (en) 2014-01-08
CN102712610B (zh) 2015-03-04
CN102712610A (zh) 2012-10-03
ECSP12012056A (es) 2012-10-30
MA33952B1 (fr) 2013-01-02

Similar Documents

Publication Publication Date Title
HN2012001351A (es) Derivados de 3- hidroxi-5-arilisotiazol novedosos
NI201700135A (es) Derivados de ciclohexano sustituido con amido
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
PE20160286A1 (es) DERIVADOS DE TIENO [2,3-c] PIRANO Y SUS COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE LA FIBROSIS QUISTICA
CU20170009A7 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
PE20151672A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
BR112013027883A2 (pt) novo derivado de 1-óxido de 3-hidroxiisotiazol
UA111579C2 (uk) ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
ECSP14013231A (es) Imidazopiridazinas sustituidas con amino
CO6321273A2 (es) N-fenil -y - lactamas subtituidas las cuales son agonistas ep2 para ser usados como agentes terapeuticos para el tratamiento de glaucoma, sindrome del intestino irritable y calvicie
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
NZ704627A (en) Spirocyclic isoxazoline parasiticidal combinations
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
PE20130815A1 (es) Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos
PE20140255A1 (es) Tableta dispersable en forma oral
CO6331308A2 (es) Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
PH12018550212A1 (en) Rotigotine behenate and preparation method and use thereof
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
NI201200196A (es) Agentes terapéuticos 976
EA201690236A1 (ru) Производные индол-3-карбинола
CY1119983T1 (el) Μεθοδος για παραγωγη ενωσης 4,4,7-τριφθορο-1,2,3,4-τετραϋδρο-5η-1-βενζαζεπινης και ενδιαμεσου προϊοντος για συνθεση εξ' αυτης
CO2019005512A2 (es) Fármaco terapéutico o fármaco profiláctico para la nefropatía diabética